Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 764532 dose-tolerability study in DLL3-positive glioma
NL-OMON60016Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- May 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of obrixtamig in glioma, sponsored by Boehringer Ingelheim. Primary endpoint: Primary endpoint(s). Started May 2024; status: active, not recruiting.
02
Drugs
obrixtamig
03
Conditions
glioma
Beyond the preview
Go deeper on NL-OMON60016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60016.